Cabaletta Bio CABA
NASDAQ CABA
$3.46 -0.02 (-0.57%)
As of: Sep 4, 2026 · 3:59 PM EDT

Cabaletta Bio (CABA) Preferred Stock Liabilities (2018 - 2019)

Cabaletta Bio (CABA) posted quarterly Preferred Stock Liabilities of $98.0 million for Q3 2019, little changed quarter-over-quarter from $98.0 million in Q2 2019.

Analysis

Cabaletta Bio (CABA) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends

Cabaletta Bio's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $98.0 million for Q3 2019.

  • In Q3 2019, Preferred Stock Liabilities changed N/A year-over-year to $98.0 million; the TTM figure through Sep 2019 stood at $98.0 million (changed N/A YoY), while the FY2018 annual figure was $43.9 million, changed N/A from the prior year.
  • Preferred Stock Liabilities for Q3 2019 stood at $98.0 million, roughly flat from $98.0 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $98.0 million in Q2 2019, with the low at $43.9 million in Q4 2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Cabaletta Bio 522.26 Mn 522.26 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 97.95 Mn
Jun 30, 2019 97.95 Mn
Dec 31, 2018 43.92 Mn